Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Venture Life ( (GB:VLG) ) just unveiled an announcement.
Venture Life Group PLC has announced the sale of its contract development and manufacturing operations, along with certain non-core products, to BioDue S.p.A for €62 million. This strategic move allows Venture Life to streamline its operations, focus on its higher-margin core brands, and invest in growth opportunities across the UK, US, and Europe. The sale is expected to enhance the company’s financial resources, enabling further investment in its existing brands and potential acquisitions. Additionally, the transaction will transform Venture Life into a pure play consumer healthcare brand platform, emphasizing ‘Proactive Healthy Longevity’ and leveraging digital capabilities for growth.
More about Venture Life
Venture Life Group PLC is a leader in product innovation, development, and commercialization within the global consumer healthcare sector. The company focuses on providing preventative and treatment solutions to support a longer, healthier life, with key brands including Balance Activ, Health & Her/Him, Lift, Earol, Pomi T, and Gelclair.
Average Trading Volume: 448,033
Technical Sentiment Signal: Buy
Current Market Cap: £57.62M
For an in-depth examination of VLG stock, go to TipRanks’ Stock Analysis page.